Harnessing the Physiological Functions of Cellular Prion Protein in the Kidneys: Applications for Treating Renal Diseases.

Abstract

A cellular prion protein (PrPC) is a ubiquitous cell surface glycoprotein, and its physiological functions have been receiving increased attention. Endogenous PrPC is present in various kidney tissues and undergoes glomerular filtration. In prion diseases, abnormal prion proteins are found to accumulate in renal tissues and filtered into urine. Urinary prion protein could serve as a diagnostic biomarker. PrPC plays a role in cellular signaling pathways, reno-protective effects, and kidney iron uptake. PrPC signaling affects mitochondrial function via the ERK pathway and is affected by the regulatory influence of microRNAs, small molecules, and signaling proteins. Targeting PrPC in acute and chronic kidney disease could help improve iron homeostasis, ameliorate damage from ischemia/reperfusion injury, and enhance the efficacy of mesenchymal stem/stromal cell or extracellular vesicle-based therapeutic strategies. PrPC may also be under the influence of BMP/Smad signaling and affect the progression of TGF-β-related renal fibrosis. PrPC conveys TNF-α resistance in some renal cancers, and therefore, the coadministration of anti-PrPC antibodies improves chemotherapy. PrPC can be used to design antibody-drug conjugates, aptamer-drug conjugates, and customized tissue inhibitors of metalloproteinases to suppress cancer. With preclinical studies demonstrating promising results, further research on PrPC in the kidney may lead to innovative PrPC-based therapeutic strategies for renal disease.

• Authors: Sungtae Yoon, Gyeongyun Go, Yeomin Yoon, Jiho Lim, Gaeun Lee, Sanghun Lee
• Journal: Biomolecules (Biomolecules) Vol. 11 Issue 6 (05 22 2021) ISSN: 2218-273X [Electronic] Switzerland
• PMID: 34067472 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antineoplastic Agents
• Neoplasm Proteins
• PrPC Proteins

Topics

• Acute Kidney Injury (drug therapy, metabolism, pathology)
• Animals
• Antineoplastic Agents (therapeutic use)
• Fibrosis
• Humans
• Kidney Neoplasms (drug therapy, pathology)
• Mitochondria (metabolism, pathology)
• Neoplasm Proteins (antagonists & inhibitors, metabolism)
• PrPC Proteins (antagonists & inhibitors, metabolism)
• Prion Diseases (drug therapy, metabolism, pathology)
• Renal Insufficiency, Chronic (drug therapy, pathology)
• Signal Transduction (drug effects)